Katie Furr, PA
Physician Assistant · Albemarle, NCNPI 1801287479
Payments from drug & device makers
Across 203 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$710
- Pfizer$434
- AbbVie$351
- Amgen$340
- Lilly USA, LLC$270
- Astellas Pharma US Inc$227
- plus $1K from 22 others
What the payments were for
- Consulting fees$1755%
- Food & beverage$3,20891%
- Education$1524%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 54 | $710 |
| Pfizer | 25 | $434 |
| AbbVie | 24 | $351 |
| Amgen | 12 | $340 |
| Lilly USA, LLC | 16 | $270 |
| Astellas Pharma US Inc | 6 | $227 |
| AstraZeneca | 13 | $193 |
| Boehringer Ingelheim | 7 | $160 |
| GSK | 7 | $137 |
| Sumitomo Pharma America, Inc. | 5 | $125 |
| Bayer | 4 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $58 |
| Exact Sciences | 3 | $55 |
| Phathom Pharmaceuticals, Inc. | 3 | $46 |
| Sanofi-aventis U.S. LLC | 2 | $45 |
| Merck | 3 | $44 |
| Mylan Specialty L.p. | 2 | $37 |
| Esperion Therapeutics, Inc. | 2 | $34 |
| Viatris Specialty LLC | 2 | $28 |
| Boston Scientific | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Kowa Pharmaceuticals America, Inc. | 1 | $22 |
| Intuity Medical Inc | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Bausch Health US, LLC | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolia$175
How this compares
$3,535 in reported general payments places this provider in the 85th percentile of 7,441 physician assistant providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 46 | $46,839 |
| OzempicSemaglutide | 33 | $41,015 |
| FarxigaDapagliflozin Propanediol | 27 | $31,849 |
| Repatha SureclickEvolocumab | 26 | $20,517 |
| JardianceEmpagliflozin | 14 | $19,779 |
| TradjentaLinagliptin | 12 | $15,100 |
| MyrbetriqMirabegron | 17 | $14,437 |
| NexlizetBempedoic Acid/Ezetimibe | 17 | $12,059 |
| JanuviaSitagliptin Phosphate | 12 | $11,951 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $10,046 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 22 | $5,040 |
| Duloxetine Hcl | 91 | $3,038 |
| Levothyroxine Sodium | 243 | $3,006 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $2,740 |
| Novolog FlexpenInsulin Aspart | 17 | $2,655 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $434 | $46,83946 claims |
| Novo NordiskOzempic | $710 | $41,01533 claims |
| Boehringer IngelheimJardiance, Tradjenta | $160 | $34,87926 claims |
| AstraZenecaFarxiga | $193 | $31,84927 claims |
| GSKTrelegy Ellipta, Shingrix | $137 | $15,08635 claims |
| Astellas Pharma US IncMyrbetriq | $227 | $14,43717 claims |
| Esperion Therapeutics, Inc.Nexlizet | $34 | $12,05917 claims |
| MerckJanuvia | $44 | $11,95112 claims |
| AbbVieSynthroid | $351 | $2,59546 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,441 physician assistant providers in North Carolina.
Other physician assistant in Albemarle
- Jo HughesGreensboro$814K
- Rachel HolzhauerCharlotte$739K
- Amber BlairCharlotte$551K
- Benjamin EpsteinDavidson$447K
- Rebecca KrausDavidson$425K
- Brooke JonesGoldsboro$259K
- Philip ReasbeckWilson$180K
- Katherine SchultzHuntersville$164K
- Kristin CabedaCharlotte$135K
- Jay ClarkeArden$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.